RxDoctor Payments Data

Carl Meisner

Family Medicine · Sugar Land, TXNPI 1184610529

Payments from drug & device makers

$500,483in general payments, 2019–2025

Across 489 payments — averaging $1023.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$271K
  • Eli Lilly$92K
  • Bayer$85K
  • Sanofi-aventis U.S. LLC$30K
  • Amgen$17K
  • AbbVie$6K
$112,510in research payments, 2019–2025

Across 169 payments — averaging $665.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$81K
  • Novo Nordisk AS$28K
  • Sanofi US Services Inc.$3K

What the payments were for

  • Travel & lodging$1,67774%
  • Food & beverage$59026%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS408$270,692
Eli Lilly29$92,159
Bayer36$84,739
Sanofi-aventis U.S. LLC5$30,268
Amgen6$17,025
AbbVie5$5,600

How this compares

$500,483 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Other family medicine in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →